At a glance
| Abbreviation | RVA |
|---|---|
| ICTV species | Rotavirus alphagastroenteritidis |
| Family | Sedoreoviridae |
| Baltimore class | III — dsRNA |
| Human infection | Human infection recorded; pattern not classified |
Also called: Rotavirus alphagastroenteritidis
Riboviria › Duplornaviricota › Resentoviricetes › Reovirales › Sedoreoviridae › Rotavirus
What it is
Taxonomy copied from ICTV MSL41.v1 / VMR_MSL41.v1.20260729.xlsx. These ranks are not hand-edited; a correction means re-running the fetch against a newer release.
| Realm | Riboviria |
|---|---|
| Kingdom | Orthornavirae |
| Phylum | Duplornaviricota |
| Class | Resentoviricetes |
| Order | Reovirales |
| Family | Sedoreoviridae |
| Genus | Rotavirus |
| ICTV identifier | ICTV19780598 |
| NCBI taxon | 3432193 |
| Exemplar isolate | Seg1: DQ838640; Seg2: DQ838635; Seg3: DQ838645; Seg4: DQ841262; Seg5: DQ838599; Seg6: DQ838650; Seg7: DQ838610; Seg8: DQ |
| Genome | Segmented, 11 segments |
Host evidence
- human: 112,017 GenBank records
- pig: 3,453 GenBank records
- cattle: 987 GenBank records (flagged for review)
- horse: 767 GenBank records (flagged for review)
- dog: 158 GenBank records (flagged for review)
- chicken: 141 GenBank records (flagged for review)
- cat: 133 GenBank records (flagged for review)
- sheep: 106 GenBank records (flagged for review)
- turkey: 47 GenBank records (flagged for review)
- goat: 46 GenBank records (flagged for review)
- water buffalo: 12 GenBank records (flagged for review)
- rabbit: 11 GenBank records (flagged for review)
Counts of nucleotide records annotated with that host. Evidence of provenance, not a statement of host range.
Where it occurs
Not searched yet. No country-level occurrence data has been curated for this virus. The WHO reported-case data on this site covers a limited set of diseases; a virus outside it gets no map rather than an empty one.
What it does
quote
FINDINGS: Worldwide in 2008, diarrhoea attributable to rotavirus infection resulted in 453,000 deaths (95% CI 420,000-494,000) in children younger than 5 years-37% of deaths attributable to diarrhoea and 5% of all deaths in children younger than 5 years.
quote
The overall case fatality risk was found to be 0.5%.
quote
The incidence of severe rotavirus gastroenteritis per 100 person-years was 1·5 in the vaccine group and 3·2 in the placebo group, with an incidence rate ratio of 0·46 (95% CI 0·33-0·65).
Lowest and highest vaccine effectiveness reported: 1% (Sow SO 2012 Vaccine; Severe rotavirus gastroenteritis, first year of follow-up, Mali site, infants dosed at approximately 6, 10 and 14 weeks, first year of follow-up) to 98% (Vesikari T 2006 N Engl J Med; Severe G1-G4 rotavirus gastroenteritis, healthy infants approximately 6 to 12 weeks old at first dose). Two of 77 estimates, each from its own study; not a summary figure.
- Randomised trial
- Pooled or expert review
- Controlled observational
When problems appear: after the infection, and after the vaccine
Two separate clocks on the same logarithmic scale. The first starts at the infection and shows when its sequelae are described as beginning; the second starts at the dose and shows when the vaccine's adverse events are described as beginning. Each bar is one source's printed window, not a synthesis; hover for the source.
- Clinical description: when it is observed to begin
- Product label observation window
- Compensation-table interval
- Study risk window: when events were counted, not typical onset
Disease risk and vaccine efficacy: every estimate with its population, design and the sentence it came from.
Vaccines
Nothing in use found in the sources searched. That is not the same as nothing existing; see the methods page for what was searched.
In development
| Name | Developer | Platform | Use | Stage | Jurisdictions | Trials | Source |
|---|---|---|---|---|---|---|---|
| ROTAVAC 5D | Bharat Biotech International Limited | Not searched yet | Routine immunisation | Phase 3 | Not searched yet | NCT06200844 | candidateId ctgov-rotavac-5d-bharat-biotech-international-limited (tar |
| Oral hexavalent reassortant rotavirus attenuated live vaccine | Sinovac Life Sciences Co., Ltd. | Not searched yet | Routine immunisation | Phase 2 | Not searched yet | NCT06967272 | candidateId ctgov-oral-hexavalent-reassortant-rotavirus-attenuated-liv |
| Rotavirus Vaccine, Live, Oral, Pentavalent | Merck Sharp & Dohme LLC | Not searched yet | Routine immunisation | Discontinued | Not searched yet | NCT01003431 | candidateId ctgov-rotavirus-vaccine-live-oral-pentavalent-merck-sharp- |
Antivirals
Not searched yet. No US-approved antiviral for this virus was found in the openFDA drug label endpoint. Only US labels were searched, and only drugs the FDA classes as antivirals.
Antibodies and immune globulins
Not searched yet. No US-approved antiviral antibody for this virus was found in the openFDA drug label endpoint.
Approval status is not a treatment recommendation. Dosing and eligibility are on the label and in national guidelines. This page does not give medical advice and does not render dosing. A development stage is not a measure of how well something works.
Related on this site
- Disease risk and vaccine efficacy — burden figures and trial results, each quoted from its source
- Rotavirus vaccine — ingredients, schedule and reported side effects
- Vaccine pipeline — candidates listed under “Rotavirus”
- Other Sedoreoviridae viruses
- Veterinary vaccines for this virus — animals, kept separate on purpose